Researchers in Prof. Karl Deisseroth's laboratory have identified a unifying endophenotype for psychosis that could be used to develop antipsychotic treatments.
Researchers in the laboratories of Dr. Karl Deisseroth and Dr. Peter Hegemann have engineered mutant ChR2 (Channelrhodopsin-2) proteins with light-sensitivity that is increased by orders of magnitude compared to wild-type ChR2.